Naringenin alleviates bone cancer pain via NF-κB/uPA/PAR2 pathway in mice
Journal of Orthopaedic Surgery · 2024-05 · 32 (2)
DOI: 10.1177/10225536241266671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Orthopaedic Surgery, online erschienen am 07.08.2024. Verfasst von Yaoyuan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Flavanones, Bone Neoplasms, NF-kappa B, Cancer Pain. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Scientific Foundation of China, CACMS Innovation Fund.
Abstract (Originalsprache)
Purpose
This investigation aims to explore the protective role of Naringenin (Nar) in bone cancer pain (BCP) via TNF-α-mediated NF-κB/uPA/PAR2 pathway.
Methods
BCP model was manipulated by the injection of LL2 cells into femur of mice. The levels of TNF-α and uPA in bone tissue and serum were studied by ELISA. The expressions of PAR2, PKC-γ, PKA and TRPV1 were determined by qPCR and western blot. Levels of p-IKKβ, IKKβ, p-p65, p65 were determined by western blot. Levels of p-p65 and uPA in bone tissue were studied by immunohistochemistry. Behavior tests in this investigation included paw withdrawal latency (PWL) and the paw withdrawal threshold (PWT). Radiological analysis and micro-CT were used to study bone structure. The lesions of bone tissue were determined by HE staining. The Dorsal root ganglia (DRG) isolated from mice were used to determine the level of PAR2 pathway.
Results
Naringenin improved the BCP-induced bone damage based on the increases of BV/TV, Conn. D, BMD and BMC and the decrease of bone destruction score. Naringenin repressed the reductions of PWT and PWL in BCP mice. Naringenin decreased the levels of PAR2, PKC-γ, PKA and TRPV1 of DRG and reduced the levels of p-IKKβ, p-p65, and uPA in serum and bone tissue in BCP. Importantly, naringenin suppressed the enhancement of TNF-α in serum and bone tissue in BCP mice.
Conclusion
Naringenin alleviated pain sensitization and bone damage of mice with BCP via TNF-α-mediated NF-κB/uPA/PAR2 pathway. We demonstrated a novel pathway for anti-BCP treatment with naringenin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- Department of Hematology and Oncology, Qinghai Provincial Hospital of Traditional Chinese Medicine, Xining, China.
ORCID-Profile: Yanju Bao
Förderung
- National Natural Scientific Foundation of China
- CACMS Innovation Fund
Zitieren
APA
Li, Y., Zheng, G., Tang, Y., Chen, Y., Yang, M., Zheng, Q., & Bao, Y. (2024). Naringenin alleviates bone cancer pain via NF-κB/uPA/PAR2 pathway in mice. Journal of Orthopaedic Surgery, 32(2). https://doi.org/10.1177/10225536241266671
Vancouver
Li Y, Zheng G, Tang Y, Chen Y, Yang M, Zheng Q, et al. Naringenin alleviates bone cancer pain via NF-κB/uPA/PAR2 pathway in mice. Journal of Orthopaedic Surgery. 2024;32(2). doi:10.1177/10225536241266671
BibTeX
@article{Li2024,
author = {Li, Yaoyuan and Zheng, Guangda and Tang, Yiting and Chen, Yupeng and Yang, Mingzhu and Zheng, Qiuhui and Bao, Yanju},
title = {Naringenin alleviates bone cancer pain via NF-κB/uPA/PAR2 pathway in mice},
journal = {Journal of Orthopaedic Surgery},
year = {2024},
volume = {32},
number = {2},
doi = {10.1177/10225536241266671}
}
EUVIMED